Skip to main content
Signal8

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

$BIIBPress releaseJul 12, 2026, 11:15 AM ETRead the release

Data presented at AAIC 2026 show Eisai and Biogen's LEQEMBI subcutaneous autoinjector is bioequivalent to the IV formulation, with an exposure ratio of 104%. The 500 mg weekly subcutaneous dose demonstrated comparable efficacy and safety to the 10 mg/kg every two weeks IV regimen, including consistent amyloid clearance and a low 1.4% incidence of anti-drug antibodies.

Key figures

Drug Name
LEQEMBI (lecanemab)
Ada incidence
1.4%
Exposure ratio
104%
Confidence interval
99.1%–109%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026 — AI Analysis | Signal8